title: Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C.
abstract: A number of potent broadly neutralizing antibodies against HIV-1 have recently been identified that target epitopes on the viral envelope that contain N-linked glycans. It remains unknown how frequently glycan-dependent neutralizing antibodies generally arise during the course of natural infection or whether particular glycosylation sites are preferentially targeted. We tested sera with a broad range of neutralization activity from individuals infected with HIV-1 clades B or C against panels of HIV-1 Env pseudoviruses that lacked specific glycans in the outer domain glycan cluster (ODGC) or inner domain glycan cluster (IDGC) to determine the presence of glycan-dependent neutralizing antibodies. Overall, 54% of individuals were observed to have neutralizing antibodies targeting these glycan regions. Glycan-specific neutralizing antibodies were readily detected in sera that were selected for having broad, moderate, or weak neutralization potency and breadth. Our results demonstrate that glycan-specific neutralizing antibodies arise with appreciable frequency in individuals chronically infected with HIV-1 clades B and C. Antibody responses that commonly occur during natural infection may be more feasible to induce by vaccination; thus glycan-specific neutralizing antibodies may be desirable responses to elicit with candidate HIV-1 vaccines.
authors.affiliation: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center , Harvard Medical School, Boston, Massachusetts.
authors.forename: Yehuda Z
authors.initials: YZ
authors.lastname: Cohen
authors.affiliation: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center , Harvard Medical School, Boston, Massachusetts.
authors.forename: Christy L
authors.initials: CL
authors.lastname: Lavine
authors.affiliation: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center , Harvard Medical School, Boston, Massachusetts.
authors.forename: Caroline A
authors.initials: CA
authors.lastname: Miller
authors.affiliation: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center , Harvard Medical School, Boston, Massachusetts.
authors.forename: Jetta
authors.initials: J
authors.lastname: Garrity
authors.affiliation: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center , Harvard Medical School, Boston, Massachusetts.
authors.forename: Brittany R
authors.initials: BR
authors.lastname: Carey
authors.affiliation: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center , Harvard Medical School, Boston, Massachusetts.
authors.forename: Michael S
authors.initials: MS
authors.lastname: Seaman
mesh_terms: D057134:Antibodies, Neutralizing / Q000097:blood*; D005838:Genotype; D015483:HIV Antibodies / Q000097:blood*; D015658:HIV Infections / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000737:chemistry* / Q000145:classification / Q000276:immunology*; D011134:Polysaccharides / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D015483:HIV Antibodies; D011134:Polysaccharides